{
  "abstract": "Background and Importance In July 2022 and August 2024, WHO declared monkeypox (MPOX) outbreaks as public health emergencies. Currently, in September 2025, cases remain uncontrolled in central-eastern Africa, and therapeutic options are almost non-existent.Tecovirimat, active against Orthopoxvirus, inhibits p37 protein, preventing viral envelope formation. In our country, it is only available via special import authorisation.Aim and Objectives To evaluate tecovirimat’s safety and efficacy through clinical data and patient feedback from MPOX cases treated at our centre.Material and Methods We analysed clinical and demographic data from patients treated between June 2022 and September 2025 at a tertiary hospital. Satisfaction was assessed using TSQM 1.4 (Treatment Satisfaction Questionnaire for Medication). All participants gave informed consent; protocol was approved by the ethics committee.Results Fourteen patients were treated (13 men, 1 trans woman; median age 36). Seven (50%) were HIV-positive, five of whom had good virological and immunological control while two had viral loads of 1,300,000 and 49,800 c/mL and CD4 + 158 and 166 per µL, respectively. Only one had previously received the MPOX vaccine.Tecovirimat was prescribed in severe cases: Among HIV+ patients, 3 had ocular lesions, 2 had poor immune control, 1 presented a polymicrobial septic shock. Among immunocompetent patients, 5 had ocular lesions (57.1% overall), 1 had brain involvement. In addition, one patient in each group didn’t respond to symptomatic treatment.Most (57.1%) received 600 mg/12h for 14 days. Two had shorter courses (5 and 7 days), the first due to early recovery (vaccinated) and the other due to an adverse event. Two received 28-days treatments (ocular lesions and dosing error) and the last two received five 14-day cycles (both with ocular lesions).TSQM scores (n=13) were effectiveness 81.7%, convenience 93.8%, global satisfaction 75.3%. Six patients (42.9%) reported mild adverse effects (stomach ache, nausea, diarrhoea); one (7.1%) developed probable toxic hepatitis (Naranjo score 5/13), requiring treatment discontinuation.Conclusion and Relevance Tecovirimat was generally safe and well tolerated, though close monitoring is advised. Vaccination may help prevent complications. Further research is needed to confirm efficacy and explore new treatments.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Medicines Department- Pharmacy Service, Barcelona, Spain"
      ],
      "name": "PM Vargas Guerras"
    },
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Medicines Department- Pharmacy Service, Barcelona, Spain"
      ],
      "name": "Á González Román"
    },
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Medicines Department- Pharmacy Service, Barcelona, Spain"
      ],
      "name": "C Alberdi Lema"
    },
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Medicines Department- Pharmacy Service, Barcelona, Spain"
      ],
      "name": "I Nos Cifré"
    },
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Medicines Department- Pharmacy Service, Barcelona, Spain"
      ],
      "name": "Y Rial Domínguez"
    },
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Medicines Department- Pharmacy Service, Barcelona, Spain"
      ],
      "name": "A Torrent Rodríguez"
    },
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Medicines Department- Pharmacy Service, Barcelona, Spain"
      ],
      "name": "M Castellà Kastner"
    },
    {
      "affiliations": [
        "Agencia Española De Medicamentos Y Productos Sanitarios Aemps, Uso Compasivo – Medicamentos En Situaciones Especiales. Departamento De Medicamentos De Uso Humano, Madrid, Spain"
      ],
      "name": "M Peraita Ezcurra"
    },
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Medicines Department- Pharmacy Service, Barcelona, Spain"
      ],
      "name": "M Tuset Creus"
    },
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Servicio De Enfermedades Infecciosas. Instituto Clínic De Medicina Y Dermatología Icmid, Barcelona, Spain"
      ],
      "name": "JL Blanco Arévalo"
    },
    {
      "affiliations": [
        "Hospital Clínic De Barcelona, Medicines Department- Pharmacy Service, Barcelona, Spain"
      ],
      "name": "D Soy Muner"
    }
  ],
  "title": "5PSQ-034 Tecovirimat against monkeypox: safety, efficacy and patient feedback",
  "uid": "844a6de1-0f16-5d72-8fe4-50c3070b2e0f"
}